NASDAQ:FLGT

Fulgent Genetics - FLGT Stock Forecast, Price & News

$31.12

+0.97 (+3.22%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $29.93
▼
$31.17
50-Day Range: $30.15
▼
$36.27
52-Week Range: $28.53
▼
$65.32

Volume: 174,978 shs
Average Volume: 315,063 shs
Market Capitalization: $918.66 million

P/E Ratio: 6.82
Dividend Yield: N/A
Price Target: $41.67

Institutional Ownership

Fulgent Genetics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 33.9% Upside
$41.67 Price Target
Short Interest: Healthy
4.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.90
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.25) to ($1.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

97th out of 1,005 stocks

Medical Laboratories Industry

4th out of 26 stocks

3.3

Analyst's Opinion

Consensus Rating
Fulgent Genetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.67, Fulgent Genetics has a forecasted upside of 33.9% from its current price of $31.12.
Amount of Analyst Coverage
Fulgent Genetics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.90% of the float of Fulgent Genetics has been sold short.
Short Interest Ratio / Days to Cover
Fulgent Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fulgent Genetics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fulgent Genetics does not currently pay a dividend.
Dividend Growth
Fulgent Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fulgent Genetics is -0.67.

3.3

News and Social Media Coverage

News Sentiment
Fulgent Genetics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.
Search Interest
60 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 275% compared to the previous 30 days.
MarketBeat Follows
10 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulgent Genetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.50% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.22% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.25) to ($1.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulgent Genetics is 6.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.01.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulgent Genetics is 6.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.32.
Price to Book Value per Share Ratio
Fulgent Genetics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in Temple City, CA.

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock News Headlines

March 24, 2023 | finance.yahoo.com

Fulgent Genetics (NASDAQ:FLGT) shareholders are still up 654% over 5 years despite pulling back 7.1% in the past week

March 16, 2023 | americanbankingnews.com

Fulgent Genetics (NASDAQ:FLGT) Research Coverage Started at StockNews.com

March 25, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

March 6, 2023 | msn.com

Looking Into Fulgent Genetics's Return On Capital Employed

March 4, 2023 | finance.yahoo.com

Earnings Beat: Fulgent Genetics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

March 3, 2023 | benzinga.com

Fulgent Genetics Stock (NASDAQ:FLGT), Dividends

March 1, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT)

March 1, 2023 | msn.com

Fulgent Genetics Non-GAAP EPS of -$0.48 beats by $0.08, revenue of $67.7M beats by $8.13M

March 25, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 1, 2023 | finance.yahoo.com

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

March 1, 2023 | finance.yahoo.com

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

March 1, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates

March 1, 2023 | finance.yahoo.com

Q4 2022 Fulgent Genetics Inc Earnings Call

February 26, 2023 | finance.yahoo.com

This Medical Play Is Up to the Test

February 23, 2023 | finance.yahoo.com

Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference

February 22, 2023 | seekingalpha.com

Fulgent Genetics: Attractive Valuation, But I Prefer To Hold For Now

February 14, 2023 | finance.yahoo.com

Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

January 3, 2023 | finance.yahoo.com

Fulgent Expands Board of Directors with Addition of Reggie Groves

December 23, 2022 | finance.yahoo.com

My Top 7 Strong Conviction Buys for 2023

December 8, 2022 | seekingalpha.com

At EV/Sales Below 1x, Fulgent Is Undervalued

December 8, 2022 | markets.businessinsider.com

Where Fulgent Genetics Stands With Analysts

December 5, 2022 | wsj.com

NASDAQ: FLGT Lawsuit Alert: Investors who lost Money with shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) should contact the Shareholders Foundation

December 2, 2022 | finance.yahoo.com

Owning 45% shares,institutional owners seem interested in Fulgent Genetics, Inc. (NASDAQ:FLGT),

November 28, 2022 | businesswire.com

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT

November 24, 2022 | finance.yahoo.com

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

November 21, 2022 | benzinga.com

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

November 21, 2022 | benzinga.com

CLASS ACTION UPDATE for FLGT, PYPL and FRSH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Company Calendar

Last Earnings: 2/28/2023
Today: 3/25/2023
Next Earnings (Estimated): 5/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FLGT
CUSIP: N/A
CIK: 1674930
Web: www.fulgentgenetics.com
Phone: (626) 350-0537
Fax: 626-454-1667
Employees: 1,012
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $41.67
High Stock Price Forecast: $45.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +33.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.56
Trailing P/E Ratio: 6.82
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $143.40 million
Net Margins: 23.17%
Pretax Margin: 29.73%
Return on Equity: 11.93%
Return on Assets: 10.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.13
Quick Ratio: 7.13

Sales & Book Value

Annual Sales: $618.97 million
Price / Sales: 1.48
Cash Flow: $6.75 per share
Price / Cash Flow: 4.61
Book Value: $43.14 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 29,520,000
Free Float: 20,811,000
Market Cap: $918.66 million
Optionable: Not Optionable
Beta: 1.61

Social Links

Key Executives

Ming Hsieh
Chairman & Chief Executive Officer

James Xie
President & Chief Operating Officer

Paul H. Kim
Chief Financial Officer

Harry Gao
Chief Scientific Officer & Laboratory Director

Lawrence M. Weiss
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FLGT Stock - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.
What is Fulgent Genetics' stock price forecast for 2023?: 3 brokers have issued twelve-month price targets for Fulgent Genetics' stock. Their FLGT share price forecasts range from $35.00 to $45.00. On average, they predict the company's stock price to reach $41.67 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.
How have FLGT shares performed in 2023?: Fulgent Genetics' stock was trading at $29.78 at the beginning of the year. Since then, FLGT shares have increased by 4.5% and is now trading at $31.12.
View the best growth stocks for 2023 here.
When is Fulgent Genetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our FLGT earnings forecast.
How were Fulgent Genetics' earnings last quarter?: Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.07. The firm had revenue of $67.70 million for the quarter, compared to analysts' expectations of $59.44 million. Fulgent Genetics had a trailing twelve-month return on equity of 11.93% and a net margin of 23.17%.
What ETFs hold Fulgent Genetics' stock?: ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer US Small Cap Cash Cows 100 ETF (CALF), Global X Genomics & Biotechnology ETF (GNOM), ETFMG Treatments Testing and Advancements ETF (GERM), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Invesco S&P SmallCap Health Care ETF (PSCH).
What guidance has Fulgent Genetics issued on next quarter's earnings?: Fulgent Genetics updated its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $56.00 million-$56.00 million, compared to the consensus revenue estimate of $60.92 million.
What other stocks do shareholders of Fulgent Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?: (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
What is Fulgent Genetics' stock symbol?: Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
Who are Fulgent Genetics' major shareholders?: Fulgent Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.71%), Pacer Advisors Inc. (1.98%), Geode Capital Management LLC (1.34%), JPMorgan Chase & Co. (1.15%), Morgan Stanley (0.90%) and American Century Companies Inc. (0.81%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.
How do I buy shares of Fulgent Genetics?: Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fulgent Genetics' stock price today?: One share of FLGT stock can currently be purchased for approximately $31.12.
How much money does Fulgent Genetics make?: Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $918.66 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or $4.56 on an earnings per share basis.
How many employees does Fulgent Genetics have?: The company employs 1,012 workers across the globe.
Does Fulgent Genetics have any subsidiaries?: The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
How can I contact Fulgent Genetics?: Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fulgent Genetics - FLGT Stock Forecast, Price & News

Fulgent Genetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fulgent Genetics (NASDAQ:FLGT) Stock

FLGT Stock News Headlines

FLGT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

FLGT Stock - Frequently Asked Questions

Overall MarketRank^™